The Effect of Control IQ Hybrid Closed Loop Technology on Glycemic Control in Adolescents and Adults with Cystic Fibrosis-Related Diabetes

Kevin J. Scully, Gurunanthan Palani, Hui Zheng, Amir Moheet, Melissa S. Putman

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Abstract

Background: Cystic fibrosis-related diabetes (CFRD) is associated with pulmonary decline, compromised nutritional status, and earlier mortality. Although diabetes technology is increasingly being used in individuals with CFRD, there is a paucity of data investigating the impact of hybrid closed loop (HCL) technology on glycemia in this patient population. Materials and Methods: In this multicenter retrospective study of 13 adults and adolescents with CFRD, 14 days of continuous glucose monitor data were analyzed at baseline, 1 and 3 months after transition to the Tandem t:slim X2 pump with Control IQ™ technology, a HCL system. Results: Control IQ initiation was associated with a significant increase in % time in target range (70-180 mg/dL), as well as decreases in average glucose, % time in hyperglycemic ranges (% time >180 mg/dL, % time >250 mg/dL), and glycemic variability (standard deviation, coefficient of variation). There was no significant change in % time in hypoglycemia ranges (% time <54 mg/dL, % time <70 mg/dL). Conclusions: To our knowledge, this is the first study to report a beneficial effect of Food and Drug Administration (FDA)-Approved HCL technology on glycemia in adults and adolescents with CFRD to date. Future studies are needed to understand the potential long-Term glycemic benefits of HCL devices and to explore the impact of this technology on heath-related quality of life, pulmonary function, nutritional status, and mortality.

Original languageEnglish (US)
Pages (from-to)446-452
Number of pages7
JournalDiabetes Technology and Therapeutics
Volume24
Issue number6
DOIs
StatePublished - Jun 1 2022

Bibliographical note

Funding Information:
M.S.P. received research funding from Vertex Pharmaceuticals in the form of an investigator initiated studies grant (unrelated to this study). The other authors have nothing to disclose.

Publisher Copyright:
© Copyright 2022, Mary Ann Liebert, Inc., publishers 2022.

Keywords

  • Continuous glucose monitor
  • Control IQ
  • Cystic fibrosis-related diabetes
  • Hybrid closed loop system

Fingerprint

Dive into the research topics of 'The Effect of Control IQ Hybrid Closed Loop Technology on Glycemic Control in Adolescents and Adults with Cystic Fibrosis-Related Diabetes'. Together they form a unique fingerprint.

Cite this